{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:26:51Z","timestamp":1790389611667,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s10096-024-04923-7","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:45:45Z","timestamp":1724345145000},"page":"2107-2115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Linezolid in enterococcal urinary tract infection: a multicentre study"],"prefix":"10.1007","volume":"43","author":[{"given":"L\u00e9a","family":"Malinowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souheil","family":"Zayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Chiaruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Baronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Klopfenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chirouze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Sotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bouiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"4923_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","volume":"7","author":"B Foxman","year":"2010","unstructured":"Foxman B (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7:653\u2013660. https:\/\/doi.org\/10.1038\/nrurol.2010.190","journal-title":"Nat Rev Urol"},{"key":"4923_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jhin.2021.04.035","volume":"116","author":"S de Lafforest","year":"2021","unstructured":"de Lafforest S, Magnier A, Vall\u00e9e M, Bey E, Le Goux C, Saint F et al (2021) FUrTIHF: French urinary tract infections in healthcare facilities - five-year historic cohort (2014\u20132018). J Hosp Infect 116:29\u201336. https:\/\/doi.org\/10.1016\/j.jhin.2021.04.035","journal-title":"J Hosp Infect"},{"key":"4923_CR3","unstructured":"Enqu\u00eate nationale de pr\u00e9valence des infections nosocomiales et des traitements anti-infectieux en \u00e9tablissements de sant\u00e9, France, mai-juin 2017. 2017;12"},{"key":"4923_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"B Foxman","year":"2014","unstructured":"Foxman B (2014) Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28:1\u201313. https:\/\/doi.org\/10.1016\/j.idc.2013.09.003","journal-title":"Infect Dis Clin North Am"},{"key":"4923_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","volume":"13","author":"AL Flores-Mireles","year":"2015","unstructured":"Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269\u2013284. https:\/\/doi.org\/10.1038\/nrmicro3432","journal-title":"Nat Rev Microbiol"},{"key":"4923_CR6","doi-asserted-by":"publisher","unstructured":"Gajd\u00e1cs M, \u00c1br\u00f3k M, L\u00e1z\u00e1r A, Buri\u00e1n K Increasing relevance of Gram-positive cocci in urinary tract infections: a 10-year analysis of their prevalence and resistance trends. Sci Rep 2020 19;10:17658. https:\/\/doi.org\/10.1038\/s41598-020-74834-y","DOI":"10.1038\/s41598-020-74834-y"},{"key":"4923_CR7","unstructured":"2015-RPC- infections_urinaires_associees_aux_soins.pdf [Internet]. [cited 2023 9];doi: https:\/\/www.infectiologie.com\/UserFiles\/File\/medias\/Recos\/2015-RPC-infections_urinaires_associees_aux_soins.pdf"},{"key":"4923_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajic.2022.05.017","volume":"51","author":"YM Garwan","year":"2023","unstructured":"Garwan YM, Alsalloum MA, Thabit AK, Jose J, Eljaaly K (2023) Effectiveness of antimicrobial stewardship interventions on early switch from intravenous-to-oral antimicrobials in hospitalized adults: a systematic review. Am J Infect Control 51:89\u201398. https:\/\/doi.org\/10.1016\/j.ajic.2022.05.017","journal-title":"Am J Infect Control"},{"key":"4923_CR9","doi-asserted-by":"publisher","unstructured":"Hollenbeck BL, Rice LB Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012 15;3:421\u2013433. https:\/\/doi.org\/10.4161\/viru.21282","DOI":"10.4161\/viru.21282"},{"key":"4923_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/AAC.28.3.446","volume":"28","author":"MJ Zervos","year":"1985","unstructured":"Zervos MJ, Schaberg DR (1985) Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother 28:446\u2013448. https:\/\/doi.org\/10.1128\/AAC.28.3.446","journal-title":"Antimicrob Agents Chemother"},{"key":"4923_CR11","unstructured":"CASFM2022_V1 0.pdf [Internet]. [cited 2023 2];doi: https:\/\/www.sfm-microbiologie.org\/wp-content\/uploads\/2022\/05\/CASFM2022_V1.0.pdf?"},{"key":"4923_CR12","doi-asserted-by":"publisher","unstructured":"Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruy\u00e8re F et al Practice guidelines for the management of adult community-acquired urinary tract infections. M\u00e9decine et Maladies Infectieuses 2018 1;48:327\u2013358. https:\/\/doi.org\/10.1016\/j.medmal.2018.03.005","DOI":"10.1016\/j.medmal.2018.03.005"},{"key":"4923_CR13","doi-asserted-by":"publisher","unstructured":"Ford C, Zurenko G, Barbachyn M The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent. CDTID 2001 1;1:181\u2013199. https:\/\/doi.org\/10.2174\/1568005014606099","DOI":"10.2174\/1568005014606099"},{"key":"4923_CR14","first-page":"1136","volume":"29","author":"JG Slatter","year":"2001","unstructured":"Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP et al (2001) Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 29:1136\u20131145","journal-title":"Drug Metab Dispos"},{"key":"4923_CR15","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","volume":"47","author":"FME Wagenlehner","year":"2003","unstructured":"Wagenlehner FME, Wydra S, Onda H, Kinzig-Schippers M, S\u00f6rgel F, Naber KG (2003) Concentrations in plasma, urinary excretion, and bactericidal activity of Linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 47:3789\u20133794. https:\/\/doi.org\/10.1128\/AAC.47.12.3789-3794.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"4923_CR16","doi-asserted-by":"publisher","unstructured":"Pontefract BA, Rovelsky SA, Madaras-Kelly KJ Linezolid to treat urinary tract infections caused by Vancomycin-resistant Enterococcus. SAGE Open Med [Internet] 2020 4 [cited 2021 5];8. doi: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7645773\/doi: https:\/\/doi.org\/10.1177\/2050312120970743","DOI":"10.1177\/2050312120970743"},{"key":"4923_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/pharmacy9040175","volume":"26","author":"MJ Wingler","year":"2021","unstructured":"Wingler MJ, Patel NR, King ST, Wagner JL, Barber KE, Stover KR (2021) Linezolid for the treatment of urinary tract infections caused by Vancomycin-Resistant Enterococci. Pharm (Basel) 26:9:175. https:\/\/doi.org\/10.3390\/pharmacy9040175","journal-title":"Pharm (Basel)"},{"key":"4923_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.purol.2021.02.005","volume":"31","author":"E Bey","year":"2021","unstructured":"Bey E, Bouiller K, Pimpie R, Le Goux C, Tourret-Arnaud J, Lina G et al (2021) Recommendations of the AFU Infectious Diseases Committee on the prevention, diagnosis and treatment of infections of endo-ureteral equipment. Prog Urol 31:557\u2013575. https:\/\/doi.org\/10.1016\/j.purol.2021.02.005","journal-title":"Prog Urol"},{"key":"4923_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/cid\/ciy418","volume":"1","author":"N Eliakim-Raz","year":"2019","unstructured":"Eliakim-Raz N, Babitch T, Shaw E, Addy I, Wiegand I, Vank C et al (2019) Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: a Multicenter Retrospective Cohort Study (RESCUING Study Group). Clin Infect Dis 1:68:29\u201336. https:\/\/doi.org\/10.1093\/cid\/ciy418","journal-title":"Clin Infect Dis"},{"key":"4923_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.rceng.2020.09.004","volume":"221","author":"E \u00c1lvarez-Artero","year":"2021","unstructured":"\u00c1lvarez-Artero E, Campo-Nu\u00f1ez A, Garc\u00eda-Garc\u00eda I, Garc\u00eda-Bravo M, Cores-Calvo O, Galindo-P\u00e9rez I et al (2021) Urinary tract infection caused by Enterococcus spp.: risk factors and mortality. An observational study. Rev Clin Esp (Barc) 221:375\u2013383. https:\/\/doi.org\/10.1016\/j.rceng.2020.09.004","journal-title":"Rev Clin Esp (Barc)"},{"key":"4923_CR21","doi-asserted-by":"publisher","unstructured":"Drekonja DM, Trautner B, Johnson JR Effect of 7 vs 14 days of Antibiotics among Afebrile Men with urinary tract infection-reply. JAMA 2021 23;326:2080\u20132081. https:\/\/doi.org\/10.1001\/jama.2021.16744","DOI":"10.1001\/jama.2021.16744"},{"key":"4923_CR22","doi-asserted-by":"publisher","unstructured":"Lafaurie M, Chevret S, Fontaine J-P, Mongiat-Artus P, de Lastours V, Escaut L et al Antimicrobial for 7 or 14 days for febrile urinary tract infection in men: a Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clin Infect Dis 2023 16;76:2154\u20132162. https:\/\/doi.org\/10.1093\/cid\/ciad070","DOI":"10.1093\/cid\/ciad070"},{"key":"4923_CR23","doi-asserted-by":"publisher","first-page":"ofad332","DOI":"10.1093\/ofid\/ofad332","volume":"10","author":"MP Bilsen","year":"2023","unstructured":"Bilsen MP, Jongeneel RMH, Schneeberger C, Platteel TN, van Nieuwkoop C, Mody L et al (2023) Definitions of urinary tract infection in current research: a systematic review. Open Forum Infect Dis 10:ofad332. https:\/\/doi.org\/10.1093\/ofid\/ofad332","journal-title":"Open Forum Infect Dis"},{"key":"4923_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/IDR.S200988","volume":"12","author":"LB Shrestha","year":"2019","unstructured":"Shrestha LB, Baral R, Khanal B (2019) Comparative study of antimicrobial resistance and biofilm formation among Gram-positive uropathogens isolated from community-acquired urinary tract infections and catheter-associated urinary tract infections. Infect Drug Resist 12:957\u2013963. https:\/\/doi.org\/10.2147\/IDR.S200988","journal-title":"Infect Drug Resist"},{"key":"4923_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41579-018-0107-z","volume":"17","author":"J-H Ch\u2019ng","year":"2019","unstructured":"Ch\u2019ng J-H, Chong KKL, Lam LN, Wong JJ, Kline KA (2019) Biofilm-associated infection by enterococci. Nat Rev Microbiol 17:82\u201394. https:\/\/doi.org\/10.1038\/s41579-018-0107-z","journal-title":"Nat Rev Microbiol"},{"key":"4923_CR26","doi-asserted-by":"publisher","unstructured":"Gaston JR, Andersen MJ, Johnson AO, Bair KL, Sullivan CM, Guterman LB et al Enterococcus faecalis Polymicrobial interactions facilitate biofilm formation, antibiotic recalcitrance, and Persistent colonization of the catheterized urinary tract. Pathogens 2020 13;9:835. https:\/\/doi.org\/10.3390\/pathogens9100835","DOI":"10.3390\/pathogens9100835"},{"key":"4923_CR27","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1128\/iai.62.10.4534-4541.1994","volume":"62","author":"N Tsuchimori","year":"1994","unstructured":"Tsuchimori N, Hayashi R, Shino A, Yamazaki T, Okonogi K (1994) Enterococcus faecalis aggravates pyelonephritis caused by Pseudomonas aeruginosa in experimental ascending mixed urinary tract infection in mice. Infect Immun 62:4534\u20134541. https:\/\/doi.org\/10.1128\/iai.62.10.4534-4541.1994","journal-title":"Infect Immun"},{"key":"4923_CR28","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1302186","volume":"14369","author":"TM Hooton","year":"2013","unstructured":"Hooton TM, Roberts PL, Cox ME, Stapleton AE (2013) Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 14369:1883\u20131891. https:\/\/doi.org\/10.1056\/NEJMoa1302186","journal-title":"N Engl J Med"},{"key":"4923_CR29","doi-asserted-by":"publisher","unstructured":"Fourcade C, Canini L, Lavigne J-P, Sotto A A comparison of monomicrobial versus polymicrobial Enterococcus faecalis bacteriuria in a French University Hospital. Eur J Clin Microbiol Infect Dis 2015 1;34:1667\u20131673. https:\/\/doi.org\/10.1007\/s10096-015-2403-0","DOI":"10.1007\/s10096-015-2403-0"},{"key":"4923_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, Lee J-Y, Chang MJ, Kim YK, Cho Y, Yu YM et al (2019) Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol 124:228\u2013234. https:\/\/doi.org\/10.1111\/bcpt.13123","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"4923_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","volume":"22","author":"Y Hanai","year":"2016","unstructured":"Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S et al (2016) A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother 22:536\u2013542. https:\/\/doi.org\/10.1016\/j.jiac.2016.05.003","journal-title":"J Infect Chemother"},{"key":"4923_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","volume":"4","author":"AM Bressler","year":"2004","unstructured":"Bressler AM, Zimmer SM, Gilmore JL, Somani J (2004) Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4:528\u2013531. https:\/\/doi.org\/10.1016\/S1473-3099(04)01109-0","journal-title":"Lancet Infect Dis"},{"key":"4923_CR33","doi-asserted-by":"publisher","unstructured":"Zhang P, Li W, Liu M, Zhan S, Zhang H, Deng G et al Linezolid-Associated Neuropathy in patients with MDR\/XDR tuberculosis in Shenzhen, China. Infect Drug Resist 2022 23;15:2617\u20132624. https:\/\/doi.org\/10.2147\/IDR.S365371","DOI":"10.2147\/IDR.S365371"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04923-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04923-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T14:03:56Z","timestamp":1730729036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04923-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4923"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04923-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study was conducted in accordance with French legislation on retrospective data studies and the Declaration of Helsinki. This is an observational study. The university hospital of Besancon Research Ethics Committee has confirmed that no ethical approval is required. The study was approved by the \u00ab D\u00e9l\u00e9gation \u00e0 la Recherche Clinique et \u00e0 l\u2019Innovation (DRCi) \u00bb of University Hospital of Besan\u00e7on, with reference number 2022\/728.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}